Medicure Inc.

195 articles with Medicure Inc.

• Medicure Reports Financial Results for Quarter Ended September 30, 2020

  11/11/2020

  Medicure Inc.cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30 , 2020.  Quarter Ended September 30, 2020 Highlights:

• Medicure Q3 2020 Results and Conference Call Dates

  11/5/2020

  Medicure Inc., a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2020 on Wednesday, November 11, 2020.

• Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar

  10/5/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the "Agreement") with Reliance Life Sciences Private Limited (&qu

• Medicure Announces AGGRASTAT Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

  8/24/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT® (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19.

• Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement

  8/20/2020

  Medicure Inc. (" Medicure " or the " Company ") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. (" Sensible

• Medicure Reports Financial Results for Quarter Ended June 30, 2020

  8/11/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020.

• Medicure Q2 2020 Results and Conference Call Dates

  8/5/2020

  Medicure Inc., a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020.

• Medicure Announces Normal Course Issuer Bid

  6/29/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").

• Medicure Announces Positive Results for AGGRASTAT in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

  6/29/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

• Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG (Pitavastatin) Tablets

  6/25/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.

• Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020

  6/15/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial.

• Medicure Reports Financial Results for Quarter Ended March 31, 2020

  5/12/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2020. 

• Medicure Q1 2020 results and conference call dates

  5/6/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended March 31, 2020 on Tuesday, May 12, 2020.

• Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019

  4/15/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2019.

• Early Warning News Release - Dr. Albert D. Friesen Holdings in Medicure Inc.

  12/31/2019

  The Issuer's head office address and Dr. Friesen's business address is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.

• Medicure Announces Preliminary Results of Substantial Issuer Bid

  12/20/2019

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, announced today the preliminary results of its substantial issuer bid (the "Offer") to repurchase for cancellation up to 4.0 million of its common shares (the "Common Shares") at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash.

• Medicure Announces the Completion of Shortened AGGRASTAT Versus Integrilin in Percutaneous Coronary Intervention (SAVI-PCI) Study

  12/17/2019

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT® (tirofiban hydrochloride) injection versus Integrilin® (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.

• Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

  12/12/2019

  The study enrolled 120 patients. Medicure expects to release top-line data in Q1 of 2020.

• Medicure Announces Settlement of Holdback Dispute from Apicore Sale

  12/5/2019

  Medicure Inc., a cardiovascular pharmaceutical company, announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement.

• Medicure Reports Financial Results for Quarter Ended September 30, 2019

  11/26/2019

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019.